Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology ...
Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines multiple myeloma research he hopes to see in the next 5 years. We really need to make an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results